Stephen L. Rawlings

Array ( [id] => 6347141 [patent_doc_number] => 20100330602 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-30 [patent_title] => 'Use of Soluble Galectin-3 (Gal-3) for Cancer Treatment' [patent_app_type] => utility [patent_app_number] => 12/441978 [patent_app_country] => US [patent_app_date] => 2007-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 23138 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0330/20100330602.pdf [firstpage_image] =>[orig_patent_app_number] => 12441978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4745653 [patent_doc_number] => 20080090255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-04-17 [patent_title] => 'Phosphoprotein detection reagent and method of making and using the same' [patent_app_type] => utility [patent_app_number] => 11/901875 [patent_app_country] => US [patent_app_date] => 2007-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14014 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0090/20080090255.pdf [firstpage_image] =>[orig_patent_app_number] => 11901875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5464989 [patent_doc_number] => 20090325189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-31 [patent_title] => 'Tyrosine phosphorylation sites' [patent_app_type] => utility [patent_app_number] => 12/311102 [patent_app_country] => US [patent_app_date] => 2007-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 34636 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 50 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0325/20090325189.pdf [firstpage_image] =>[orig_patent_app_number] => 12311102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6320352 [patent_doc_number] => 20100113339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-06 [patent_title] => 'Serum albumin binding proteins with long half-lives' [patent_app_type] => utility [patent_app_number] => 12/310756 [patent_app_country] => US [patent_app_date] => 2007-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16154 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0113/20100113339.pdf [firstpage_image] =>[orig_patent_app_number] => 12310756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4964822 [patent_doc_number] => 20080107642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-05-08 [patent_title] => 'ANTIBODIES AGAINST GPR64 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 11/852155 [patent_app_country] => US [patent_app_date] => 2007-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 20610 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0107/20080107642.pdf [firstpage_image] =>[orig_patent_app_number] => 11852155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4733394 [patent_doc_number] => 20080050373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-02-28 [patent_title] => 'TREATMENT WITH ANTI-ERBB2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 11/851298 [patent_app_country] => US [patent_app_date] => 2007-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 15807 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0050/20080050373.pdf [firstpage_image] =>[orig_patent_app_number] => 11851298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4807809 [patent_doc_number] => 20080171387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-07-17 [patent_title] => 'Method for modulating cell proliferation' [patent_app_type] => utility [patent_app_number] => 11/847520 [patent_app_country] => US [patent_app_date] => 2007-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5696 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0171/20080171387.pdf [firstpage_image] =>[orig_patent_app_number] => 11847520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4663056 [patent_doc_number] => 20080253963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-10-16 [patent_title] => 'Tumor markers in ovarian cancer' [patent_app_type] => utility [patent_app_number] => 11/895326 [patent_app_country] => US [patent_app_date] => 2007-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15792 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0253/20080253963.pdf [firstpage_image] =>[orig_patent_app_number] => 11895326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3746 [patent_doc_number] => 07811568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-10-12 [patent_title] => 'Smallpox monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 11/843415 [patent_app_country] => US [patent_app_date] => 2007-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3425 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/811/07811568.pdf [firstpage_image] =>[orig_patent_app_number] => 11843415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4807478 [patent_doc_number] => 20080171056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-07-17 [patent_title] => 'USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS' [patent_app_type] => utility [patent_app_number] => 11/840584 [patent_app_country] => US [patent_app_date] => 2007-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 22619 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0171/20080171056.pdf [firstpage_image] =>[orig_patent_app_number] => 11840584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4675538 [patent_doc_number] => 20080213167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-09-04 [patent_title] => 'USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS' [patent_app_type] => utility [patent_app_number] => 11/840573 [patent_app_country] => US [patent_app_date] => 2007-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 22615 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0213/20080213167.pdf [firstpage_image] =>[orig_patent_app_number] => 11840573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4675631 [patent_doc_number] => 20080213260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-09-04 [patent_title] => 'USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS' [patent_app_type] => utility [patent_app_number] => 11/840576 [patent_app_country] => US [patent_app_date] => 2007-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 22616 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0213/20080213260.pdf [firstpage_image] =>[orig_patent_app_number] => 11840576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4675539 [patent_doc_number] => 20080213168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-09-04 [patent_title] => 'USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS' [patent_app_type] => utility [patent_app_number] => 11/840580 [patent_app_country] => US [patent_app_date] => 2007-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 22616 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0213/20080213168.pdf [firstpage_image] =>[orig_patent_app_number] => 11840580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4965272 [patent_doc_number] => 20080108092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-05-08 [patent_title] => 'Monoclonal antibody for NKX3.1 and method for detecting same' [patent_app_type] => utility [patent_app_number] => 11/837756 [patent_app_country] => US [patent_app_date] => 2007-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8112 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0108/20080108092.pdf [firstpage_image] =>[orig_patent_app_number] => 11837756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4669780 [patent_doc_number] => 20080044840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-02-21 [patent_title] => 'ANTIBODIES AGAINST CANCER ANTIGEN TMEFF2 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 11/837333 [patent_app_country] => US [patent_app_date] => 2007-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16499 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0044/20080044840.pdf [firstpage_image] =>[orig_patent_app_number] => 11837333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4802610 [patent_doc_number] => 20080014197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-01-17 [patent_title] => 'NEUTRALIZING HUMAN ANTI-IGFR ANTIBODY' [patent_app_type] => utility [patent_app_number] => 11/835791 [patent_app_country] => US [patent_app_date] => 2007-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25338 [patent_no_of_claims] => 83 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0014/20080014197.pdf [firstpage_image] =>[orig_patent_app_number] => 11835791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9238676 [patent_doc_number] => 08603465 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2013-12-10 [patent_title] => 'Methods for treatment of polyposis' [patent_app_type] => utility [patent_app_number] => 11/834303 [patent_app_country] => US [patent_app_date] => 2007-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12252 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11834303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4431169 [patent_doc_number] => 07968098 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-06-28 [patent_title] => 'HLA-A24-binding KIF-derived peptide' [patent_app_type] => utility [patent_app_number] => 12/309950 [patent_app_country] => US [patent_app_date] => 2007-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6792 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/968/07968098.pdf [firstpage_image] =>[orig_patent_app_number] => 12309950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4751908 [patent_doc_number] => 20080159981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-07-03 [patent_title] => 'Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein' [patent_app_type] => utility [patent_app_number] => 11/888699 [patent_app_country] => US [patent_app_date] => 2007-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14598 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0159/20080159981.pdf [firstpage_image] =>[orig_patent_app_number] => 11888699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4718544 [patent_doc_number] => 20080241066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-10-02 [patent_title] => 'Anti-PRL-3 antibodies and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 11/881274 [patent_app_country] => US [patent_app_date] => 2007-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 12165 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0241/20080241066.pdf [firstpage_image] =>[orig_patent_app_number] => 11881274 [rel_patent_id] =>[rel_patent_doc_number] =>)